Proteomics of resistance to anticancer drugs. We have used proteomics to identify several proteins that are up- or down-regulated by the widely used platinum based anti-cancer drug cisplatin. These proteins are potential targets for modulating the activity of cisplatin.
Proteomics and the detection of breast cancer . Fluid can be obtained easily by non-invasive procedures from breasts and is called nipple aspirate fluid (NAF). The proteome of NAF is relatively simple having about 100 proteins. We have identified approximately 50% of these. Three were shown to be down-regulated in NAF taken from breasts in which cancer had been diagnosed. These proteins were further studied in a larger NAF sample from 200 women, where it was shown that expression of the proteins correlated with the presence of breast cancer. This work paves the way to the development of a kit for the diagnosis of breast cancer.
Proteomics and lymphoma. Dogs are treated for cancer with many of the same drugs as humans. We have studied the differences between cell from normal and lymphoma lymphnodes. Several candidate proteins have been identified and we are now determining how the expression of these proteins responds to drug therapy.
McCaw, D. L., Chan, A.S., Stegner, A.L., Mooney, B., Bryan, J.N, Turquist, S.E., Henry, C.J., Alexander, H., and Alexander, S. (2007) Proteomics of canine lymphoma identifies potential cancer specific protein markers. Clin Cancer Res 13: 2496-2503.
Alexander, H., Stegner, A.L., Wagner-Mann, C., Du Bois, G.C., Alexander, S., and Sauter, E.R. (2004). Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10: 7500-7510.